Galera Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Galera Therapeutics's estimated annual revenue is currently $5.6M per year.(i)
  • Galera Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • Galera Therapeutics has 28 Employees.(i)
  • Galera Therapeutics grew their employee count by -32% last year.

Galera Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder, Executive Chair & Chief Operating OfficerReveal Email/Phone
2
CSOReveal Email/Phone
3
SVP, Regulatory AffairsReveal Email/Phone
4
Controller Galera Therapeutics, Inc.Reveal Email/Phone
5
VP Commercial OperationsReveal Email/Phone
6
VP Market AccessReveal Email/Phone
7
SVP, Clinical Operations and Data ManagementReveal Email/Phone
8
Director, ITReveal Email/Phone
9
Chief Financial OfficerReveal Email/Phone
10
Director, Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is Galera Therapeutics?

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$5.6M

Revenue (est)

-32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Galera Therapeutics News

2022-04-20 - Galera to Present at 2022 American Society of Clinical ...

MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe...

2022-04-13 - Financial Survey: Galera Therapeutics (NASDAQ:GRTX ...

Financial Survey: Galera Therapeutics (NASDAQ:GRTX) versus Prestige Consumer Healthcare (NYSE:PBH). Posted by admin on Apr 22nd, 2022.

2022-04-06 - Galera Therapeutics, Inc. (NASDAQ:GRTX) Receives $12.45 ...

Galera Therapeutics, Inc. (NASDAQ:GRTX) Receives $12.45 Consensus PT from Analysts. Posted by admin on Apr 17th, 2022.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.7M28-10%N/A
#2
$8.5M3011%N/A
#3
$3.5M30-14%N/A
#4
$5.5M31-3%N/A
#5
$6.1M317%N/A